Physicochemical Properties
| Molecular Formula | C51H88O60S13 |
| Molecular Weight | 2078.05 |
| CAS # | 1144617-49-1 |
| SMILES | S(=O)(=O)(O)OC1C(C(C(COS(=O)(=O)O)OC1OC1CC[C@]2(C)[C@@H](C1)CC[C@H]1[C@@H]2CC[C@@]2(C)[C@@H](C(C)CCCC(C)C)CC[C@@H]21)OC1C(C(C(C(COS(=O)(=O)O)O1)OC1C(C(C(C(COS(=O)(=O)O)O1)OC1C(C(C(C(COS(=O)(=O)O)O1)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O |
| Synonyms | PG545 free acid |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Synthetic heparan sulfate mimetic pixatimod (PG545) potently inhibits SARS-CoV-2 by disrupting the spike–ACE2 interactionJ. ACS central science, 2022, 8(5): 527-545. [2]. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors. J Immunother Cancer. 2023 Jan;11(1):e006136. |
Solubility Data
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4812 mL | 2.4061 mL | 4.8122 mL | |
| 5 mM | 0.0962 mL | 0.4812 mL | 0.9624 mL | |
| 10 mM | 0.0481 mL | 0.2406 mL | 0.4812 mL |